Sign in
CompletedNo phase

S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)

Key facts

Who runs it
Medical University of Warsaw
Where
Poland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
1 Sept 2023
Ended
1 Jan 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • S-Adenosyl-L-methionine (SAMe)
  • Placebo
Record updated
25 August 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • primary sclerosing cholangitis fulfilling EASL criteria
  • age: 18 - 75 years
  • treatment with ursodeoxycholic acid (UDCA) in a dose of 13-15mg/kg b.w. for at least 6 months

Who cannot take part

  • treatment with: steroids, statins, rifampicin, antidepressants
  • patients with other forms of chronic liver diseases
  • other diseases or states that can affect quality of life and mood: decompensated diabetes mellitus, renal insufficiency requiring dialyses, malignancy, heart failure ≥ New York Heart Association (NYHA) II, organ transplantation, known HIV infection, rheumatoid arthritis, asthma, psychiatric disorders
  • history of hypersensitivity reactions to S-adenosylmethionine
  • any other condition, which in the opinion of the investigators would impede the patient's participation or compliance in the study
  • inability to give informed consent
  • decompensated liver cirrhosis (Child-Pugh class B-C)
  • patients with PSC who underwent stenting of their biliary tree within 6 months
  • pregnant or breastfeeding women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to investigate clinical effects (liver biochemistries, health-related quality of life, liver stiffness) and underlying mechanisms of hepatoprotection of S-adenosylmethionine in patients with primary sclerosing cholangitis. The study will be performed in a randomized and placebo-controlled fashion.

The 2 groups in the trial

  • S-adenosylmethionine (SAMe)Treatment being tested

    Participants randomized to SAMe Group will receive S-adenosyl-L-methionine 1200 mg/daily (as 2400mg SAMe disulfate tosylate) in tablets in two divided doses (800mg in the morning and 400mg midday) over the period of 6 months. In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg b.w.

    Treatment: S-Adenosyl-L-methionine (SAMe)

  • PlaceboPlacebo, for comparison

    Patients in Placebo Group will receive a placebo of identical appearance, smell and taste, with the same schedule. In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg.In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg b.w.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Effect and Molecular Mechanisms of Action of S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)
Record updated
25 August 2026